Tools for Practice Outils pour la pratique

#123 A Serendipitous Discovery and Novel Treatment for Infantile Hemangiomas

Are beta-blockers effective in treating small infantile hemangiomas?

One small randomized controlled trial (RCT) and numerous observational studies demonstrate that oral propranolol stops growth and induces regression of infantile hemangiomas (IH) by four weeks. Similar evidence suggests topical timolol stops IH growth and induces regression by >5% after 4-6 months for every one in 2-3 patients. 

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Oral Propranolol: 
  • RCT (40 children, aged nine weeks to five years, followed x 6.0 months).1 Compared to placebo, propranolol 2mg/kg (divided three times per day) statistically significantly: 
    • Stopped IH growth by week four for all children. 
    • Reduced IH volume at all weeks (example Week 12: -48.5% vs. +17.9%). 
    • No significant hypotension, hypoglycemia, or bradycardia. 
  • Systematic review (40 observational studies plus above RCT,1 1,264 children, mean age 6.6 months, treated x 6.4 months):2
    • Mean response rate (any improvement) 98%. 
    • Serious side effects rare: symptomatic hypotension, bradycardia, or hypoglycemia in ten. 
Topical Timolol: 
  • RCT (41 children, median nine weeks old).3 At 20-24 weeks, significantly more IHs with one drop timolol maleate 0.5% gel twice a day vs. placebo: 
    • Decreased in size by >5% (vs. normal increase in size at this age) Number Needed to Treat (NNT)=3. 
    • Limitations: Small numbers. 
  • Prospective clinical study (124 children, ≤12 months age).4 At four months, significantly more in timolol group than observational group reported:     
    • IH stopped growing and/or became smaller, 92% vs. 34%, NNT=2. 
    • No serious adverse events. 
  • Numerous smaller retrospective cohort and prospective clinical studies report similar findings.5-9 
  • Beta-blockers for IH first reported in 2008 when two infants started on propranolol for cardiac reasons experienced dramatic involution of severe hemangiomas.10 
  • Hemangiomas often develop in the first few weeks of life, reach 80% of their final size by three months and 80% complete growth by five months.11 By five years the majority of lesions completely disappear without treatment.12 
  • Oral propranolol FDA-approved for severe IHs.13 No beta-blocker approved by Health Canada for this. 

Latest Tools for Practice
Derniers outils pour la pratique

#370 Antibiotics or no antibiotics for acute diverticulitis, that is the question!

Do antibiotics change clinical outcomes for patients with acute uncomplicated diverticulitis?
Read Lire 0.25 credits available Crédits disponibles

#369 Remind me, do medications that target brain amyloid improve my dementia?

Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment or Alzheimer’s dementia?
Read Lire 0.25 credits available Crédits disponibles

#368 Sodium Restriction in Heart Failure: Beneficial or pouring salt in the wound?

Does sodium restriction improve outcomes in patients with chronic heart failure?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Christina Korownyk MD CCFP
  • Loretta Fiorillo MD FRCPC

1. Hogeling M, Adams S, Wargon O. Pediatrics. 2011; 128(2):e259-66.

2. Marqueling AL, Oza V, Frieden IJ, et al. Pediatr Dermatol. 2013; 30(2):182-91.

3. Chan H, McKay C, Adams S, et al. Pediatrics. 2013; 131(6):e1739-47.

4. Yu L, Li S, Su B, et al. Exp Ther Med. 2013; 6(2):388-390.

5. Pope E, Chakkittakandiyil A. Arch Dermatol. 2010; 146:564-5.

6. Ni N, Langer P, Wagner R, et al. Arch Ophthalmol. 2011; 129:377-9.

7. Chambers CB, Katowitz WR, Katowitz JA, et al. Ophthal Plast Reconstr Surg. 2012; 28(2):103-6.

8. Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Pediatr Dermatol. 2012. Jan-Feb; 29(1):28-31.

9. Moehrle M, Léauté-Labrèze C, Schmidt V, et al. Pediatr Dermatol. 2013; 30:245-9.

10. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. N Engl J Med. 2008; 358:2649-51.

11. Chang LC, Haggstrom AN, Drolet BA, et al. Pediatrics. 2008; 122(2):360-7.

12. Jacobs AH. Calif Med. 1957; 86(1):8-10.

13. June 2014 Approved Drug Product List. Available at: Accessed September 4, 2014.

Authors have no conflicts of interest to declare.